Reordenamiento de la oferta de servicios de salud para la atención de recién nacidos en Lima Metropolitana en las IPRESS del Ministerio de Salud, 2015-2019: Reorganization of the offer of health services for the care of newborns in Metropolitan Lima in the IPRESS of the Ministry of Health, 2015-2019

Neonatal maternal morbidity and mortality is a public health problem in Peru. The Ministry of Health (MINSA) has designed various interventions to address this problem, such as family planning, delivery care by a health professional, and refocused prenatal care; which are part of the Budgetary Program (PP) Maternal Neonatal Health that is executed in the health establishments of the country of the MINSA and the Regional Governments.  La morbimortalidad materno-neonatal es un problema de salud pública en el Perú. El Ministerio de Salud ha diseñado diversas intervenciones que permiten enfrentar este problema tales como planificación familiar, atención del parto por profesional de salud y atención prenatal reenfocada; las cuales son parte del Programa Presupuestal (PP) Salud Materno Neonatal que es ejecuta en los establecimientos de salud del país del MINSA y de los Gobiernos Regionale

Evaluación de Tecnologías Sanitarias (ETS) en el Perú: estado actual y retos futuros

A health technology (drug, vaccine, medical device, procedure) is submitted to a systematic evaluation procedure, called Health Technology Assessment (HTA). The HTA process involves analyzing the properties, benefits, risks and costs of a technology applied to health care, and issuing evidence-based information, linking research and its findings with decision-making in the field of health. Based on the recommendations obtained as a result of the HTA, decision-makers in the health sector choose to admit or reject the incorporation of new health technologies. In Peru, as in the rest of the world, the health technology assessment process has been implemented for approximately ten years, and there are institutions with experience in preparing reports with the results of the HTA. This article provides a general overview of HTA in the world, with special emphasis on their evolution and development in Peru.Una tecnología sanitaria (medicamento, vacuna, dispositivo médico, procedimiento) es sometida a un procedimiento sistemático de valorización, denominado evaluación de tecnologías sanitarias (ETS). El proceso de ETS conlleva analizar una tecnología aplicada a la atención sanitaria, y emitir información basada en evidencias, vinculando la investigación y sus hallazgos con la toma de decisiones en el ámbito de la salud. En base a las recomendaciones obtenidas como resultado de la ETS, los encargados de decidir en el sector salud optan por admitir o rechazar la inclusión de nuevas tecnologías en el ámbito sanitario. En el Perú, al igual que en el resto del mundo, la ETS se ha implementado desde hace aproximadamente diez años, existiendo instituciones con experiencia en la elaboración de informes con los resultados de la ETS. El presente artículo brinda un panorama general de las ETS en el mundo, con especial énfasis en su evolución y desarrollo en el Perú

Características socioeconómicas y costos de enfermedades raras y huérfanas en el Perú, 2019: Socioeconomic characteristics and costs of rare and orphan diseases in Peru, 2019

Introduction: The rare and orphan diseases (ROD) constitute a current challenge due to the lack of investigation. Objective: Describe the socioeconomic characteristics of rare and orphan diseases (ROD) in Peru, 2019. Methods: Descriptive observational design. The information was obtained from FISSAL administrative records, and an intentional sample of 20 patients was taken to carry out the questionnaire on ROD. For the economic records, a review of the public budget of the MEF was made. The data analysis was descriptive and inferential. Results: There were 454 patients with a total of 49 ROD; of these, the most representative age groups were schoolchildren and young adults (18% each), and the most frequent diagnosis was Tetralogy of Fallot (22%). The questionnaire on ROD reports a median of 7 months in the delay of diagnosis and between 3 and 5 doctors were visited. Likewise, 30% considered that it generated a high to very high expense. It was calculated that the ROD budget constitutes 2.25% of the total budget for high-cost diseases. Likewise, the ROD budget was different between 2014 and 2019. Conclusions: The population with ROD in Peru is not large; however, it requires greater attention to access to health services and a greater budget allocation.Introducción: Las enfermedades raras y huérfanas (ERH) constituyen un desafío actual debido a la poca atención que se les da. Objetivo: Describir las características socioeconómicas de las enfermedades raras y huérfanas (ERH) en el Perú, 2019. Métodos: Diseño observacional descriptivo. Se obtuvo la información a partir de registros administrativos del FISSAL y se tomó una muestra intencional de 20 pacientes para realizar el cuestionario sobre ERH. Para los registros económicos se hizo una revisión del presupuesto público del MEF. El análisis de datos fue descriptivo e inferencial. Resultados: Hubo 454 pacientes con un total de 49 ERH, de estos, los grupos de edades más representativos fueron los escolares y adultos jóvenes (18% cada uno) y el diagnóstico más frecuente fue la Tetralogía de Fallot (22%). Del cuestionario sobre ERH se reporta una mediana de 7 meses en la demora del diagnóstico y se visitó entre 3 y 5 médicos. Asimismo, el 30% consideró que le generó un gasto entre alto y muy alto. Se calculó que el presupuesto para ERH constituye el 2,25% del presupuesto total para enfermedades de alto costo, asimismo, el presupuesto para ERH fue diferente entre los años 2014 y 2019. Conclusión: La población con ERH en el Perú no es numerosa; sin embargo, requiere una mayor atención para el acceso a los servicios de salud, así como una mayor asignación presupuestal

Cadena de Frío del Programa Nacional de Inmunizaciones Peruano en el Contexto de la Pandemia COVID-19: Cold chain of the Peruvian National Immunization Program in the context of the COVID-19 pandemic

Objective: The aim of this study was to identify critical aspects of the Cold Chain in the immunization process in Peru. Methodology: A descriptive study was conducted, analyzing data from the Ministry of Economy and Finance (MEF) and the Ministry of Health (MINSA) for the years 2020-2021, as well as administrative records from the MINSA's Regional Health Strategies for immunizations in 2020. Technical aspects established in the Health Technical Standard for Cold Chain Management, such as obsolescence, allocation, functionality, and storage capacity were taken into account. Results: In the year 2020, at the national level, 61.8% of the cold chain equipment showed obsolescence, with some regions exceeding 75%, with Lima’s metropolitan region being the most affected at 88%. Concerning equipment allocation, 9% of the first-level health facilities lacked refrigeration equipment, with Loreto having the highest deficit (46%), followed by Huancavelica with a 21% gap. The overall equipment functionality nationwide was 84%, meaning that 16% of health facilities experienced technical failures, affecting vaccine’s storage capacity and posing risks to their safety and immunogenicity. Significant gaps were identified when considering quarterly or monthly storage for COVID-19 vaccines or other health emergencies. Conclusions: This study highlights potential risks in the operability and storage capacity of the national immunization program's vaccines in Peru during contingencies such as the COVID-19 pandemic or other health emergencies.Objetivo: Identificar aspectos críticos de la Cadena de Frío en el Perú Metodología: Estudio descriptivo. Se analizaron datos del Ministerio de Economía y Finanzas (MEF) y del Ministerio de Salud (MINSA) de los años 2020-2021, así como los registros administrativos de las Estrategias Sanitarias Regionales de inmunizaciones del MINSA en 2020. Se consideraron aspectos técnicos de la Norma Técnica de Manejo de cadena de frío, como es obsolescencia, dotación, funcionalidad y capacidad de almacenamiento. Resultados: En el año 2020, en términos de obsolescencia el 61.8% de los equipos de cadena de frío a nivel nacional presentaban obsolescencia, siendo regiones claves como Lima Metropolitana (capital del país) la más afectada con un 88%. En cuanto a la dotación de equipos, el 9% de los establecimientos de salud del primer nivel carecen de equipos de refrigeración, siendo Loreto la región con mayor déficit 46%, seguida de Huancavelica con un 21% de brecha. En términos de funcionamiento, se registra que el 84% de los equipos a nivel nacional funcionan, y el 16% reportan fallas técnicas, lo cual representa alto riesgo en la seguridad y potencia inmunogénica de las vacunas a prever. En términos de capacidad, al considerar el almacenamiento trimestral o mensual para las vacunas contra la COVID-19 u otras emergencias sanitarias se identificaron brechas significativas. Conclusiones: Existen riesgos en la operatividad, suministro y capacidad de almacenamiento de las vacunas del esquema nacional de inmunizaciones de Perú incluso ante emergencias sanitarias

Use of evidence in heath policies and programs contributions of the Instituto Nacional de Salud

This article analyzes some examples about how the Ministry of Health of Peru has used evidence for policy and program formulation, implementation and evaluation. It describes the process by which health budget programs are based and strengthened with scientific evidence. Provides an overview about how the development of clinical guidelines methodology is facilitating the generation of high quality evidence based clinical guidelines.It presents some examples of specific information needs of the Ministry of Health to which the Instituto Nacional de Salud has responded, and the impact of that collaboration. Finally, the article proposes future directions for the use of research methodology especially relevant for the development and evaluation of policy and programs, as well as the development of networks of health technology assessment at the national and international level

Time-efficient three-dimensional transmural scar assessment provides relevant substrate characterization for ventricular tachycardia features and long-term recurrences in ischemic cardiomyopathy

Delayed gadolinium-enhanced cardiac magnetic resonance (LGE-CMR) imaging requires novel and time-efficient approaches to characterize the myocardial substrate associated with ventricular arrhythmia in patients with ischemic cardiomyopathy. Using a translational approach in pigs and patients with established myocardial infarction, we tested and validated a novel 3D methodology to assess ventricular scar using custom transmural criteria and a semiautomatic approach to obtain transmural scar maps in ventricular models reconstructed from both 3D-acquired and 3D-upsampled-2D-acquired LGE-CMR images. The results showed that 3D-upsampled models from 2D LGE-CMR images provided a time-efficient alternative to 3D-acquired sequences to assess the myocardial substrate associated with ischemic cardiomyopathy. Scar assessment from 2D-LGE-CMR sequences using 3D-upsampled models was superior to conventional 2D assessment to identify scar sizes associated with the cycle length of spontaneous ventricular tachycardia episodes and long-term ventricular tachycardia recurrences after catheter ablation. This novel methodology may represent an efficient approach in clinical practice after manual or automatic segmentation of myocardial borders in a small number of conventional 2D LGE-CMR slices and automatic scar detection.The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación and the ProCNIC Foundation (Madrid, Spain). The CNIC and the Barcelona Supercomputing Center (BSC, Barcelona, Spain) are Severo Ochoa Centers of Excellence (SEV-2015-0505 and SEV-2011-0067, respectively). This study was also supported by grants from the Fondo Europeo de Desarrollo Regional (CB16/11/00458), the Ministerio de Ciencia e Innovación (PID2019-109329RB-I00) and the Heart Rhythm Association of the Spanish Society of Cardiology (ARC). The study was also part of a Master Research Agreement between CNIC and Philips Healthcare. The study was partially supported by the Fundación Interhospitalaria para la Investigación Cardiovascular (FIC, Madrid, Spain) and the Fundación Eugenio Rodríguez Pascual (Madrid, Spain). J.A.-S. is funded by the CompBioMed2 project grant agreement 823712, H2020-EU.1.4.1.3 European Union’s Horizon 2020 research and innovation program, the SILICOFCM project, grant agreement 777204, H2020-EU.3.1.5 and by a Ramón y Cajal fellowship (RYC-2017-22532), MINECO, Spain. L.K.G was funded by the Fundación Carolina-BBVA. Grant TEC2017-82408-R is also acknowledged.Peer Reviewed"Article signat per 25 autors/es: Susana Merino-Caviedes, Lilian K. Gutierrez, José Manuel Alfonso-Almazán, Santiago Sanz-Estébanez, Lucilio Cordero-Grande, Jorge G. Quintanilla, Javier Sánchez-González, Manuel Marina-Breysse, Carlos Galán-Arriola, Daniel Enríquez-Vázquez, Carlos Torres, Gonzalo Pizarro, Borja Ibáñez, Rafael Peinado, Jose Luis Merino, Julián Pérez-Villacastín, José Jalife, Mariña López-Yunta, Mariano Vázquez, Jazmín Aguado-Sierra, Juan José González-Ferrer, Nicasio Pérez-Castellano, Marcos Martín-Fernández, Carlos Alberola-López & David Filgueiras-Rama"Postprint (published version